Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AT-1501-I206: An Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Transplanted Islet Cells and AT-1501 Immunomodulation in Adults With Brittle Type 1 Diabetes

NCT05480657 is registered in ClinicalTrials.gov with Eledon Pharmaceuticals as lead sponsor.

NCT NCT05480657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05480657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AT-1501-I206: An Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Transplanted Islet Cells and AT-1501 Immunomodulation in Adults With Brittle Type 1 Diabetes
Lead sponsor
Eledon Pharmaceuticals
Phase
Phase 1/2
Overall status
Withdrawn
Start date
September 30, 2022
Completion date
August 31, 2028
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brittle type 1 diabetes mellitus